Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 3/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5642064 | 0.87 | LOXL2 (0.60) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL7549813 | 0.82 | LOXL2 (0.59) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL5586763 | 0.82 | LOXL2 (0.55) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL6156791 | 0.82 | LOXL2 (0.55) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL4333117 | 0.82 | LOXL2 (0.59) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL2592547 | 0.79 | LOXL2 (0.60) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| Alcohol SCHEMBL7142853 | 0.79 | LOXL2 (0.51) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL4760639 | 0.78 | LOXL2 (0.50) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL653529 | 0.78 | LOXL2 (0.63) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL325463 | 0.78 | LOXL2 (0.58) | LOXL2MTNR1AMTNR1BHRH3AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240726-A1 | COMPOSITIONS FOR TREATING AMYLOID ASSOCIATED DISEASES | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2010-09-23 | — | — | US | claimed |
| US-20080194667-A1 | Type II diabetes mellitus, Alzheimer's dementia or diseases, systemic and localized amyloidosis; indole-3-carbinol (3-hydroxymethyl indole), 3-hydroxyindole, and 4-hydroxyindole | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT (IL) | 2008-08-14 | — | — | US | claimed |
| EP-1793816-A2 | COMPOSITIONS FOR TREATING AMYLOID ASSOCIATED DISEASES | Tel Aviv University Future Technology Development L.P. (IL) | 2007-06-13 | — | — | EP | claimed |
| WO-2006018850-A2 | COMPOSITIONS FOR TREATING AMYLOID ASSOCIATED DISEASES | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2006-02-23 | — | — | WO | claimed |
| US-8889729-B2 | Compositions for treating amyloid associated diseases | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2014-11-18 | — | — | US | disclosed |
| US-20110183928-A1 | 3-Cyanoalkyl- and 3-hydroxyalkylindoles and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-28 | — | — | US | disclosed |
| US-20100240726-A1 | COMPOSITIONS FOR TREATING AMYLOID ASSOCIATED DISEASES | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2010-09-23 | — | — | US | disclosed |
| US-7732479-B2 | Type II diabetes mellitus, Alzheimer's dementia or diseases, systemic and localized amyloidosis; indole-3-carbinol (3-hydroxymethyl indole), 3-hydroxyindole, and 4-hydroxyindole | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2010-06-08 | — | — | US | disclosed |
| US-20080194667-A1 | Type II diabetes mellitus, Alzheimer's dementia or diseases, systemic and localized amyloidosis; indole-3-carbinol (3-hydroxymethyl indole), 3-hydroxyindole, and 4-hydroxyindole | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT (IL) | 2008-08-14 | — | — | US | disclosed |
| EP-1793816-A2 | COMPOSITIONS FOR TREATING AMYLOID ASSOCIATED DISEASES | Tel Aviv University Future Technology Development L.P. (IL) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006018850-A2 | COMPOSITIONS FOR TREATING AMYLOID ASSOCIATED DISEASES | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2006-02-23 | — | — | WO | disclosed |
| WO-2004041781-A1 | PREPARATION OF 3-AMINOALKYL-SUBSTITUTED INDOLE DERIVATIVES FROM PHENYLHYDRAZINES AND AMINOKETONES | SUVEN LIFE SCIENCES LIMITED (IN) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240726-A1 | COMPOSITIONS FOR TREATING AMYLOID ASSOCIATED DISEASES | IAPP, PSEN2, PRNP | LOXL2 460/4885MTNR1A 309/4885MTNR1B 241/4885 |
| US-20080194667-A1 | Type II diabetes mellitus, Alzheimer's dementia or diseases, systemic and localized amyloidosis; indole-3-carbinol (3-hydroxymethyl indole), 3-hydroxyindole, and 4-hydroxyindole | IAPP, TPH2, IDO2 | LOXL2 552/4885MTNR1A 359/4885MTNR1B 172/4885 |
| US-20110183928-A1 | 3-Cyanoalkyl- and 3-hydroxyalkylindoles and use thereof | HTR3C, HTR3A, ADRB3 | LOXL2 472/4885MTNR1A 310/4885MTNR1B 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.